498 related articles for article (PubMed ID: 12151908)
1. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
2. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Thomas A; Iacono D; Bonanni L; D'Andreamatteo G; Onofrj M
Clin Neuropharmacol; 2001; 24(1):31-42. PubMed ID: 11290880
[TBL] [Abstract][Full Text] [Related]
3. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia.
Onofrj M; Thomas A; Iacono D; Luciano AL; Di Iorio A
Clin Neuropharmacol; 2003; 26(5):239-51. PubMed ID: 14520164
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
Katada E; Sato K; Sawaki A; Dohi Y; Ueda R; Ojika K
J Geriatr Psychiatry Neurol; 2003 Mar; 16(1):39-43. PubMed ID: 12641372
[TBL] [Abstract][Full Text] [Related]
5. Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Chang YS; Chen HL; Hsu CY; Tang SH; Liu CK
J Clin Neurophysiol; 2014 Feb; 31(1):81-5. PubMed ID: 24492450
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
7. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
[TBL] [Abstract][Full Text] [Related]
8. Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
10. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Reeves RR; Struve FA; Patrick G; Booker JG; Nave DW
Am J Geriatr Psychiatry; 1999; 7(4):349-52. PubMed ID: 10521169
[TBL] [Abstract][Full Text] [Related]
11. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Vaitkevičius A; Kaubrys G; Audronytė E
Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
[TBL] [Abstract][Full Text] [Related]
12. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.
Nobili F; Vitali P; Canfora M; Girtler N; De Leo C; Mariani G; Pupi A; Rodriguez G
Clin Neurophysiol; 2002 Aug; 113(8):1241-8. PubMed ID: 12140003
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
15. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
17. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
18. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Weiner MF; Martin-Cook K; Foster BM; Saine K; Fontaine CS; Svetlik DA
J Clin Psychiatry; 2000 Jul; 61(7):487-92. PubMed ID: 10937606
[TBL] [Abstract][Full Text] [Related]
19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
20. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
